Timing note: UHS will release 2Q26 results after the market close on Monday, July 27, 2026, with the earnings call scheduled for Tuesday, July 28 at 9:00 a.m. ET. So the report is due today, rather than tomorrow.
UHS enters 2Q with an unusually visible earnings tailwind: management disclosed at its June investor conference that it expects roughly $100 million of retroactive benefit from Florida’s approved 2025 Medicaid supplemental-payment program to be recognized in 2Q. That should make the headline result—and likely the reported EBITDA/EPS comparison—look very strong.
The more important issue for investors is whether the core business has accelerated enough to support or raise the existing 2026 framework after adjusting for that discrete benefit. In 1Q, UHS delivered solid reported growth, but acute-care volumes were flat and investors focused on a softer underlying earnings run rate after stripping out supplemental payments, weather/flu effects, and other non-core items.
The 2Q report should therefore resolve four questions:
UHS’s 2026 guidance remains broad:
| 2026 guidance | Range |
|---|---|
| Revenue | $18.4B–$18.8B |
| Adjusted EBITDA net of NCI | $2.64B–$2.79B |
| Adjusted EPS | $22.64–$24.52 |
| Same-facility volume growth, acute and behavioral | 2%–3% |
| Capital expenditures | $950M–$1.10B |
Management reiterated this outlook with 1Q results, but said it would reassess it with the 2Q release. That makes guidance the central catalyst, particularly because the initial plan excluded unapproved Florida supplemental payments.
In 1Q26, UHS reported:
| 1Q26 metric | Result | YoY change |
|---|---|---|
| Revenue | $4.50B | +9.6% |
| Adjusted EBITDA net of NCI | $648M | +8.4% |
| Adjusted EPS | $5.62 | +16.1% |
| Operating cash flow | $402M | +11.5% |
The operational detail was more mixed:
The key investor concern was that 1Q contained substantial Medicaid supplemental-payment benefits while the “clean” core-growth trajectory appeared softer. Management acknowledged that core earnings growth would need to improve through the year to achieve its approximately 5% underlying-growth objective.
The expected ~$100 million retroactive Florida 2025 program benefit is the most important reported-results item in the quarter. It was not included in the original 2026 outlook, and it should materially improve 2Q earnings.
However, investors should separate two distinct issues:
A guidance increase that simply captures the Florida retroactive payment would be positive but not necessarily evidence of better core operations. A raise plus improved volume or margin commentary would be a stronger signal.
Management entered the year expecting 2%–3% same-facility volume growth in both major segments. The first quarter was knowingly below that target because of seasonality, weather, and flu comparisons. By March, management said volumes had returned to a more normal growth cadence, so 2Q is the first cleaner test of the full-year thesis.
UHS added meaningful acute capacity during 2Q:
The existing-market expansions should ramp faster because they build on established referral networks. By contrast, Palm Beach Gardens will be a near-term profitability drag; management has characterized the first year of a new hospital as a ramp period and expects the facility to approach divisional performance more gradually.
Also important is Cedar Hill in Washington, D.C. UHS expects improvement there to be weighted toward the second half of 2026. Investors should look for evidence that the facility’s volume and earnings ramp is beginning to improve, even if the larger contribution remains a 2H event.
Behavioral is strategically important because UHS is attempting to shift from an inpatient-centric model to a broader continuum of outpatient, step-down, and virtual care.
The bullish setup is straightforward:
The needed proof point is sustained patient-day growth above the 1.6% recorded in 1Q, along with labor-cost moderation. California’s new inpatient psychiatric staffing rules took effect on June 1, 2026, creating a planned $35 million pretax headwind for 2026; 2Q will contain the initial costs and any census disruption associated with implementation.
UHS’s 2026 outlook incorporates an estimated $75 million pretax headwind from lower health-insurance-exchange coverage. The company expects many patients losing subsidized coverage to continue using the ER, but with a greater portion of care becoming self-pay or uninsured—making this primarily a collectibility and bad-debt issue rather than a volume issue.
In 1Q:
By June, management said its assumptions still appeared reasonable, but it needed more time to assess the loss of coverage and the recovery rate on claims. The 2Q release should offer a much clearer read on whether the $75 million reserve is sufficient.
UHS expects to close the Talkspace acquisition in early 3Q26. The deal is intended to provide a national virtual behavioral-health platform and a network of approximately 6,000 clinicians, complementing UHS’s inpatient facilities, outpatient clinics, and “1,000 Branches” initiative.
Management’s financial claims are ambitious:
For this quarter, the focus should be on closing timing, financing, and integration milestones, rather than earnings contribution. UHS established a $400 million delayed-draw term loan specifically to fund the transaction. More recently, it also added a separate $700 million delayed-draw term loan available through September 30 for general corporate purposes, including refinancing debt and related fees; that facility does not explicitly designate Talkspace as its use.
Despite the acquisition and elevated capital spending, UHS has remained committed to buybacks. It repurchased 675,000 shares for $127 million in 1Q and had approximately $1.30 billion remaining under its authorization at quarter-end.
Management has said it expects leverage to remain in the low-2x range following Talkspace—within its longstanding 2x–3x preferred range—and views the share price as compelling. This supports continued repurchases alongside outpatient investment and selective M&A.
That said, investors should monitor free-cash-flow conversion because 2026 capex remains elevated, the new Florida hospital is in start-up mode, and acquisition financing will increase interest expense.
UHS closed at $155.78 on Friday, July 24, down approximately 28.5% from its December 31, 2025 close of $218.02. The shares also fell roughly 4.2% on April 28, when UHS reported 1Q results. The setup therefore appears skeptical: the market is discounting uncertainty around policy exposure, normalized core earnings growth, and the durability of supplemental Medicaid payments.
This creates a favorable asymmetry if UHS can demonstrate that:
Conversely, a headline beat driven primarily by the Florida retroactive payment—without evidence of better underlying volumes, margins, or 2H earnings power—may not be enough to change the narrative.
Reported 2Q earnings should benefit materially from Florida supplemental payments, but the investment case hinges on underlying momentum. A constructive report would pair the discrete Florida benefit with normalized volume growth, stable exchange-related bad debt, improving behavioral labor productivity, and a more confident second-half outlook. A less constructive outcome would show that the reported beat is mostly nonrecurring, while core growth, payer mix, and new-facility ramp remain uneven.